Concordia International Corp Company Review & Valuation
About Concordia International Corp
Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products.
The company operates through two segments, Concordia International and Concordia North America.
The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.
This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye.
The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria.
This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells.
The company sells its products through direct sales and local partnerships.
The company was formerly known as Concordia Healthcare Corp.
and changed its name to Concordia International Corp.
Concordia International Corp.
is headquartered in Oakville, Canada.